ALK immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients

被引：0
|
作者：
Metro, G. [1 ]
Chiari, R. [1 ]
Giannarelli, D. [2 ]
Sidoni, A. [1 ]
Bellezza, G. [1 ]
机构：
[1] Azienda Osped Perugia S Maria della Misericordia, Perugia, Italy
[2] Ist Regina Elena, Rome, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(18)30307-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
27P
引用
收藏
页码：S14 / S15
页数：2
相关论文
共 50 条
  • [1] Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients
    Metro, Giulio
    Giannarelli, Diana
    Sidoni, Angelo
    Chiari, Rita
    Bellezza, Guido
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2018, 33 (04): : 549 - 550
  • [2] Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
    Martinez, Pablo
    Hernandez-Losa, Javier
    Angeles Montero, M.
    Cedres, Susana
    Castellvi, Josep
    Martinez-Marti, Alex
    Tallada, Natalia
    Murtra-Garrell, Nuria
    Navarro-Mendivill, Alejandro
    Rodriguez-Freixinos, Victor
    Canela, Mercedes
    Ramon y Cajal, Santiago
    Felip, Enriqueta
    PLOS ONE, 2013, 8 (01):
  • [3] ASSESSMENT OF ALK REARRANGEMENT IN ADVANCED NON-SMALL CELL LUNG CANCER USING FLUORESCENCE IN SITU HYBRIDIZATION & IMMUNOHISTOCHEMISTRY
    Han, X.
    Ma, L.
    Liu, Y.
    Zhang, N. N.
    Li, D.
    Shi, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 390 - 390
  • [4] An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib
    Shi, Ruoshi
    Varella-Garcia, Marileila
    Li, Ming
    Ludkovski, Olga
    Danesh, Arnavaz
    Ng, Christine
    Pham, Nhu-An
    Pugh, Trevor
    Shepherd, Frances A.
    Tsao, Ming-Sound
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (12) : 2248 - 2252
  • [5] The analysis of ALK gene rearrangement by fluorescence in situ hybridization in non-small cell lung cancer patients
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel Adam
    Ramlau, Rodryg Adam
    Szumilo, Justyna
    Kozielski, Jerzy
    Kalinka-Warzochas, Ewa
    Bryl, Maciej
    Knopik-Nabrowicz, Alina
    Spychalski, Lukasz
    Szczesna, Aleksandra
    Rydzik, Ewelina
    Milanowski, Janusz
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2013, 17 (06): : 484 - 492
  • [6] ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report.
    Khadija, Kalai
    Auger, Nathalie
    Lueza, Beranger
    Commo, Frederic
    Valent, Alexander
    Rousseau, Vanessa
    Dorvault, Nicolas
    Friboulet, Luc
    Olaussen, Ken
    Rajpar, Laetitia
    Planchard, David
    Lacroix, Ludovic
    Pignon, Jean-Pierre
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative
    Ma, Di
    Wang, Zheng
    Yang, Lin
    Mu, Xinlin
    Wang, Yan
    Zhao, Xinming
    Li, Junling
    Lin, Dongmei
    ONCOTARGET, 2016, 7 (39) : 64410 - 64420
  • [8] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
  • [9] ALK status in a series of non-small cell lung cancer (NSCLC) using fluorescence in situ hybridization (FISH)
    Salido, Marta
    Galvan, Ana B.
    Gimeno, Javier
    -Rivera, Maria Rodriguez
    Pijuan, Lara
    Espinet, Blanca
    Albanell, Joan
    Arriola, Edurne
    Serrano, Sergi
    Sole, Francesc
    CHROMOSOME RESEARCH, 2011, 19 : S162 - S163
  • [10] Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
    Nishio, Makoto
    Kim, Dong-Wan
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Solomon, Benjamin J.
    Shaw, Alice T.
    Hashigaki, Satoshi
    Ohki, Emiko
    Usari, Tiziana
    Paolini, Jolanda
    Polli, Anna
    Wilner, Keith D.
    Mok, Tony
    CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 691 - 700
12345